Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet Lond Engl, vol.387, issue.16, pp.4-4, 2016. ,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, vol.361, pp.947-57, 2009. ,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, vol.362, pp.2380-2388, 2010. ,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-285, 2012. ,
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, vol.31, pp.3327-3361, 2013. ,
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas, Eur Respir Rev, vol.23, pp.356-66, 2014. ,
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, vol.462, pp.1070-1074, 2009. ,
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, vol.372, pp.1689-99, 2015. ,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, vol.316, pp.1039-1082, 2007. ,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib ,
, , vol.104, pp.20932-20939, 2007.
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay, Clin Cancer Res, vol.17, pp.1169-80, 2011. ,
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, vol.3, 2011. ,
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, vol.19, pp.2240-2247, 2013. ,
MET FISHpositive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation, BMC Cancer, vol.15, p.31, 2015. ,
MET amplification status in therapy-naïve adeno-and squamous cell carcinomas of the lung, Clin Cancer Res, vol.21, pp.907-922, 2015. ,
MET amplification, protein expression, and mutations in pulmonary adenocarcinoma, Lung Cancer Amst Neth, vol.90, pp.381-388, 2015. ,
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer, Oncotarget, vol.7, pp.51311-51319, 2016. ,
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification, J Thorac Oncol, vol.11, pp.83-85, 2016. ,
Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer, Cancer Discov, vol.6, pp.1335-1341, 2016. ,
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients, Lung Cancer Amst Neth, vol.75, pp.89-94, 2012. ,
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients, J Clin Oncol, vol.27, pp.1667-74, 2009. ,
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients, Ann Oncol, vol.20, pp.298-304, 2009. ,
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, vol.311, 1998. ,
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC), Oncotarget, vol.6, pp.16215-16241, 2015. ,
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?, Diagn Pathol, vol.10, p.130, 2015. ,
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort, J Thorac Oncol, vol.3, pp.331-340, 2008. ,
Efficacy and safety of crizotinib in patients with advanced www.impactjournals.com/oncotarget c-MET-amplified non-small cell lung cancer (NSCLC), J Clin Oncol, vol.32, p.5, 2014. ,
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis, J Thorac Oncol, vol.11, pp.1293-304, 2016. ,
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells, Oncotarget, vol.7, p.27379, 2016. ,
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis, Clin Cancer Res, vol.22, pp.3048-56, 2016. ,
Gastrointestinal malignancies harbor actionable MET exon 14 deletions, Oncotarget, vol.6, pp.28211-28233, 2015. ,
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFRmutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation, Clin Cancer Res, vol.17, pp.1616-1638, 2011. ,
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors, Lung Cancer Amst Neth, vol.82, pp.294-302, 2013. ,
MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis, PloS One, vol.9, 2014. ,
Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures, PloS One, vol.9, 2014. ,
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC, Cancer Cell, vol.17, pp.77-88, 2010. ,
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMETpositive (cMET+) non-small cell lung cancer (NSCLC), J Clin Oncol, vol.34, 2016. ,
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations, Cancer, vol.119, pp.4325-4357, 2013. ,